Adult T-cell leukemia future or investigational therapies

Adult T-cell leukemia Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adult T-cell leukemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray Findings
Echocardiography and Ultrasound
CT scan
MRI Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Adult T-cell leukemia future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adult T-cell leukemia future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adult T-cell leukemia future or investigational therapies
CDC on Adult T-cell leukemia future or investigational therapies
Adult T-cell leukemia future or investigational therapies in the news
Blogs on Adult T-cell leukemia future or investigational therapies
Directions to Hospitals Treating Adult T-cell leukemia
Risk calculators and risk factors for Adult T-cell leukemia future or investigational therapies

Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.